Antidepressants – TCAs Intro
The TCAs: Introduction
The tricyclic antidepressants TCAs are a group of drugs of similar structure (hence their tag of TCA, which refers to their arrangement in three-rings), but they are markedly heterogeneous in terms of their pharmacological actions. Some of them can be considered as mis-classified in that they are not actually antidepressants at all. They therefore illustrate that although the structural similarity of drugs may be close, their pharmacological actions can be very different. For instance, clomipramine is a close structural analogue of chlorpromazine, but their effects could hardly be more different. See clomipramine:
Any discussion that generalises by saying ‘the tricyclics …’ is certain to be unhelpful and equally certain to be inaccurate (e.g. see the appalling APA textbook chapter on TCAs about which I have commented [link]). See also my seminal review paper about the TCAs (1). [link]
When they were introduced in the early 1960s these drugs were labelled as either anti-histamines, or anti-depressants (according to how their properties were then perceived), some were mis-classified (e.g. doxepin should have been classified as an anti-histamine, and chlorpheniramine as an anti-depressant). Some readers may realise than in fact doxepin has recently been ‘rebadged’ as a sleeping tablet (only 50 years too late! But that is psychiatrists’ knowledge of pharmacology for you!). I have been using it as a hypnotic for twenty-five years or so, nice to see people catching up at last. The rationale behind that is explicated in my TCA review paper (free pdf here), see table 6.
It is logical to select a few of the TCAs for antidepressant treatment and familiarise oneself with the use of those. The notes on ‘receptor affinities’ and ‘toxicity’ clarify and substantiate the rationale for the following preferences, see the TCA review paper (1).
Clomipramine: is probably still be the best and cheapest serotonin and noradrenalin reuptake inhibitor SNRI (But note recent ‘price gouging’ here [link]).
Nortriptyline: potent as a noradrenalin reuptake inhibitor, modest but useful sedative effect, low anti-muscarinic effect, linear pharmacokinetics, no active metabolites, no significant inhibition of cytochrome P450 enzymes, cheap. Can be safely combined with both an SRI (preferably sertraline and an MAOI: so is a good ‘bridging’ drug.
Amitriptyline: evidence for superior efficacy vs SRIs in severe depression (but many regard clomipramine as a more potent AD).
Imipramine/Desipramine: best side effect vs potency profile (Desipramine), particularly the lowest propensity to cause postural hypotension or anti-muscarinic side effects (note lofepramine (2) is similar and is metabolised into desipramine (3)). But Desipramine is very potent and the usually recommended dose range is very probably much too high (link).
TCAs vs the rest
Selected tricyclic antidepressants remain important and effective first choice (‘first-line’) treatments for major depressive disorder (4). The relatively higher toxicity of some of them in overdose (especially dothiepin– see ‘toxicity’), and other side effects, persuade some authorities to over-generalise, over-simplify and say they are no-longer suitable for ‘first-line’ treatment in primary care. Nonsense, in the sense of ‘non-sense’. The discontinuation rates due to SEs are not meaningfully different for selected TCAs and newer ADs. Indeed, in my experience patients are less likely to need to cease NTP than SSRIs.
The evidence on toxicity does not logically support the widely advocated, but simplistic, approach of avoiding TCAs because they might have higher toxicity if someone takes an OD. To start with, some TCAs are less toxic than some ‘newer’ drugs (e.g. nortriptyline is less toxic than venlafaxine). Also, note that some 95% of deaths by suicide are not caused by the antidepressant drug prescribed, so prescribing a less toxic drug does not address the main problem of death from suicide attempts. That is especially so if the shiny new drug is, in reality, less effective (which some, perhaps many, of the newer drugs probably are). Indeed, the evidence that some old drugs are more effective than most of the new drugs remains strong– especially for amitriptyline, imipramine and clomipramine and tranylcypromine, phenelzine isocarboxazid (see other notes).
The risk of suicide, even if that is by over-dose with the prescribed TCA, is minimised by ‘good clinical management’ (e.g. among other measures, patients should be attending frequently (or be in hospital), only a small (sub-lethal) supply may be issued at each visit, if no responsible person is available to supervise the supply. Remember, 95% of those who die by suicide use means other than the drug they are prescribed.
Misinformed views about SEs and toxicity have caused most doctors to make SSRIs their ‘default’ choice (follow the ‘guidelines’, then you do not have to think for yourself!).
There are good reasons not to use SRIs as ‘first-line’ for some patients (see below), but most doctors are ignorant of what these are, to their patients’ detriment.
When to consider avoiding SRIs as first choice
We can predict which patients are likely to find a TCA to be a more satisfactory option as a first-choice treatment:
Typical “endogenous” symptom profile, or more severe, depressive illness.
Patients with previous episodes of severe depression unresponsive, or partially responsive, to an SSRI).
Those whose current episode is severe or who show psychomotor retardation or lack of energy (optimal choices, imipramine, amitriptyline and clomipramine, my preference is definitely for clomipramine because it is an ‘SNRI”).
Those with pre-existing history of, or present symptoms of, marked insomnia. Also patients with restless leg syndrome, which is precipitated and exacerbated by SRIs.
Those with previous or present symptoms of gastrointestinal disturbance, reflux, dyspepsia, GI ‘overactivity, GI bleed, or any bleeding tendency or propensity for bruising.
Those with anorexia and weight loss.
Those with present, or past, history of significant suicidal features or attempts. Such patients may be made worse by SSRIs.
Those with high anxiety or agitation.
If concern over cytochrome P450 enzyme drug interactions is relevant. TCAs cause less problems in this area than many new drugs.
A history of hyponatremia.
Any concern regarding discontinuation or withdrawal syndromes should be a cause for caution and careful consideration of alternative strategies.
The above factors, and others, will indicate a TCA may be the optimal first choice.
Gillman’s maxim No. 2
The longer a new drug is in use the smaller its side effect advantages turn out to be, compared with previously existing drugs.
I am astonished that others took so long to appreciate the problems caused by SRIs in relation to bleeding, serious GI problems and frequent, almost unavoidable, sexual dysfunction, not to mention interactions caused by CYP450 inhibition.
That demonstrates the power of indoctrination by advertising.
There is evidence from both clinical experience and research that SSRIs noticeably increase the risk of gastric disturbance and bleeds. This is probably for two reasons; they are ‘pro-kinetic’ in the GI tract (hence the side effect of diarrhoea) and they increase the bleeding time (by depleting platelet 5-HT). It is astonishing that everyone seems to have forgotten so quickly that depletion of platelet 5-HT was the assay initially used indicate whether a drug was an SRI!
A quick point here about ‘side effects’, which is a mis-used term. The main so-called side effects of many drugs, particularly SSRIs, are an inevitable consequence of their main intended mechanism of action, as illustrated by increased bleeding time caused by depletion of platelet 5-HT, gastric upset, sexual dysfunction. Hence they occur in all subjects, to a greater or lesser degree.
It behoves us all to be sceptical about SEs and alert to the emergence of long-term problems — such problems are still emerging with SSRIs after 30 years! E.g. see (5-7), and most recently the spectre of autism possibly being exacerbated or even caused by SRIs in pregnancy (8, 9). Post marketing surveillance in most countries is a relatively neglected area; we must not expect that side effects will always be obvious.
Sertraline, like nortriptyline, has a particularly favourable pharmacokinetic and side effect profile with a lesser propensity for interactions and is a 1st choice (10). It is also a weak dopamine re-uptake inhibitor and that may confer significant advantage, particularly in relation to the insidious amotivational syndrome that I think is underappreciated as an effect of SRIs (see note on bupropion).
Three of the other selective serotonin reuptake inhibitors have significant and sometimes dangerous interactions, mostly via cytochrome P450 enzymes; these are fluoxetine (2D6 and 3A4), paroxetine (2D6) and fluvoxamine (1A2 and 2C9 /19). For this reason, it is hard to justify their routine use by primary care doctors who are likely to encounter difficulties keeping up with the multiple possible interactions. Some of these interactions have precipitated serious morbidity and have led to expensive litigation.
SSRIs are often an inadequate treatment for more severe depressive illness.
I advise great caution if treating “endogenous” depression with these drugs, one often encounters degrees of improvement that fall well short of full remission of illness. That is unacceptable, because full remission of illness is the goal.
Less effective drugs probably include; moclobemide, citalopram, paroxetine, fluvoxamine, trimipramine, doxepin, dothiepin, trazodone, nefazodone and mianserin and its cousin 6-azamianserin marketed as mirtazapine.
Although the old monoamine oxidase inhibitors (MAOIs), tranylcypromine and phenelzine, are no longer advertised (how many young doctors do not know they even exist?) it is well to remember that they are not just very effective, but are the treatment of choice for some patients.
The therapeutic effectiveness of many new drugs for major depression is not yet satisfactorily established (and probably never will be), yet a large proportion of doctors rush to use the most recently approved drug on the flimsiest of evidence.
1. Gillman, PK, Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol, 2007. 151(6): p. 737-48.
2. Bolden-Watson, C and Richelson, E, Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci., 1993. 52(12): p. 1023-9.
3. Lancaster, SG and Gonzalez, JP, Lofepramine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs, 1989. 37(2): p. 123-40.
4. Arroll, B, Macgillivray, S, Ogston, S, Reid, I, et al., Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med, 2005. 3(5): p. 449-56.
5. Laporte, S, Chapelle, C, Caillet, P, Beyens, MN, et al., Bleeding Risk under Selective Serotonin Reuptake Inhibitor (Ssri) Antidepressants: A Meta-Analysis of Observational Studies. Pharmacol. Res., 2016.
6. Jiang, HY, Chen, HZ, Hu, XJ, Yu, ZH, et al., Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol, 2015. 13(1): p. 42-50 e3.
7. Anglin, R, Yuan, Y, Moayyedi, P, Tse, F, et al., Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am. J. Gastroenterol., 2014. 109(6): p. 811-9.
8. Gentile, S, Prenatal antidepressant exposure and the risk of autism spectrum disorders in children. Are we looking at the fall of Gods? J Affect Disord, 2015. 182: p. 132-7.
9. Clements, CC, Castro, VM, Blumenthal, SR, Rosenfield, HR, et al., Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol. Psychiatry, 2015. 20(6): p. 727-34.
10. Cipriani, A, Furukawa, TA, Geddes, JR, Malvini, L, et al., Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis. J Clin Psychiatry, 2008.